Edgar Lomax Co. VA Sells 5,400 Shares of Medtronic PLC $MDT

Edgar Lomax Co. VA decreased its holdings in Medtronic PLC (NYSE:MDT) by 1.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 337,085 shares of the medical technology company’s stock after selling 5,400 shares during the period. Medtronic comprises approximately 1.9% of Edgar Lomax Co. VA’s investment portfolio, making the stock its 20th biggest holding. Edgar Lomax Co. VA’s holdings in Medtronic were worth $29,384,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in MDT. 1248 Management LLC bought a new stake in Medtronic in the 1st quarter valued at $26,000. Twin Tree Management LP bought a new position in shares of Medtronic in the first quarter valued at about $29,000. Activest Wealth Management lifted its stake in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after buying an additional 322 shares during the last quarter. GFG Capital LLC bought a new stake in shares of Medtronic during the 2nd quarter worth about $36,000. Finally, True Wealth Design LLC grew its stake in Medtronic by 49.8% in the 2nd quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock valued at $37,000 after buying an additional 140 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. Robert W. Baird boosted their price target on Medtronic from $103.00 to $109.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Cowen reaffirmed a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Wells Fargo & Company lifted their target price on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Finally, Argus boosted their target price on shares of Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.72.

Medtronic Stock Up 1.8%

Shares of NYSE MDT opened at $101.16 on Monday. The stock has a market capitalization of $129.76 billion, a P/E ratio of 27.87, a PEG ratio of 2.42 and a beta of 0.77. The stock’s fifty day moving average is $95.04 and its 200 day moving average is $91.00. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $102.59. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.